Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00447577
Status:
COMPLETED
Last Update Posted:
2011-12-09
First Post:
2007-03-12
Brief Title:
Zylet vs TobraDex in Blepharokeratoconjunctivitis
Sponsor:
Bausch Lomb Incorporated
Organization:
Bausch Lomb Incorporated
Study Overview
Official Title:
A Clinical Safety and Efficacy Evaluation of Zylet Loteprednol Etabonate and Tobramycin Ophthalmic Suspension vs Tobradex Tobramycin and Dexamethasone Ophthalmic Suspension in the Treatment of Blepharokeratoconjunctivitis
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to evaluate the safety and efficacy of Zylet vs Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None